Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- DLB +10.2%, TAL +9.4%, VAR +8.5%, AVT +5.2%, LRCX +4.8%, (promotes Tim Archer to President, effective immediately), APTS +4.6%, XLNX +4.1%, NURO +4.1%, BIIB +3.2%, OSK +3.2%, PX +3%, MKC +2.9%, FCAU +2.8%, MMM +2.8%, CAT +2.8%, LLL +2.5%, FFIV +2.4%, STM +2.2%, DEO +1.9%, CELG +1.8%, LUV +1.6%, DDE +1.6%, HP +1.3%, AEP +1.3%, NOC +1%, LVS +0.7%
Other news:
- LTBR +104.2% (Lightbridge and Framatome to host press conference with live webcast regarding anticipated 'major corporate development' on January 25 at 10:05am ET)
- SMMT +30.9% (announces 'positive' 24-week interim results from the open-label Phase 2 proof of concept clinical trial, PhaseOut DMD )
- SSTI +15% (ShotSpotter announces agreement with Verizon to bring the ShotSpotter solution to cities by leveraging Verizon's Light Sensory Network)
- ANGO +8.7% (ticking higher; receives FDA Expedited Access Pathway designation to the Company's NanoKnife System and proposed indication for use for the treatment of Stage III pancreatic cancer )
- AYX +7.8% (rebounding after sale of shares by CEO was disclosed last night - was part of trading plan)
- IOVA +6.1% (reported preliminary data from C-145-03 and C-145-04; announces co will offer $125 million of its common stock)
- AMSC +5.6% (continued strength after announcing its first 5.5 megawatt electrical control systems order from South Korea's Doosan Heavy Industries)
- SGYP +5.1% (announces FDA approval of TRULANCE (Plecanatide) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults)
- LGF.A +4.6% (following Vice Chairman Burns appearance on CNBC Fast Money)
- ONCE +3.9% (Spark Therapeutics enters into licensing agreement with Novartis (NVS) to develop and commercialize investigational voretigene neparvovec outside the U.S.)
- AMAT +2.4% (following LRCX results)
- ENDP +2.3% (agrees to FDA's request to seek temporary litigation stay; hopeful that the policy changes FDA has described, once effective, will address the multiple concerns that led Endo to file this case)
Analyst comments:
- OBLN +7.8% (upgraded to Market Perform from Under Perform at Northland Capital)
- SNN +4.4% (upgraded to Overweight from Neutral at JP Morgan)
- CTL +4.1% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- HZO +3.2% (upgraded to Buy from Neutral at CL King)
- CRI +1.6% (upgraded to Outperform from Market Perform at Wells Fargo)
- GLDD +1% (initiated with a Buy at Noble Financial)
- LOW +0.7% (upgraded to Outperform at Telsey Advisory Group)